What Are The Chances Of Seres Therapeutics Inc (NASDAQ: MCRB) Becoming A Clear Buy?

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. The stock was recently discussed on Yahoo Finance as it revealed that Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

As a NASDAQ listed company, MCRB falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $1.14 and fluctuated between $1.2350 as its day high and $1.1300 as its day low. The current market capitalization of Seres Therapeutics Inc is $147.36M. A total of 4.69 million shares were traded on the day, compared to an average of 4.64M shares.

Insider Activity

Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, MCRB has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 10 BUYs and 9 SELLs from insiders. Insiders purchased 175,556 shares during that period but sold 41,807.

In the most recent transaction, Shaff Eric D. sold 11,549 shares of MCRB for 1.08 per share on Feb 16. After the transaction, the CEO and President now owns 135,321 company shares. In a previous transaction on Feb 16, Ege David S. sold 5,010 shares at 1.08 per share. MCRB shares that the insider owns now total 73,856.

Among the insiders who sold shares, von Moltke Lisa disposed of 4,400 shares on Feb 16 at a per-share price of $1.08. This resulted in the insider holding 16,988 shares of MCRB after the transaction. In another insider transaction, Henn Matthew R. sold 4,170 shares at $1.08 per share on Feb 16. Company shares held by the insider now total 63,436.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, MCRB has a high of $6.87 and a low of $0.91.

As of this writing, MCRB has an earnings estimate of -$0.5 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.33 per share and a lower estimate of -$1. The company reported an EPS of $0.36 in the last quarter, which was -32.10% lower than expectations of $0.53.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. MCRB’s latest balance sheet shows that the firm has $290.71M in Cash & Short Term Investments as of fiscal 2021. There were $49.21M in debt and $82.26M in liabilities at the time. Its Book Value Per Share was -$0.12, while its Total Shareholder’s Equity was $131.51M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MCRB is Buy with a score of 4.67.

Most Popular

Related Posts